News

SkylineDx Enhances Multiple Myeloma Risk Profiling with SKY92 Test

SkylineDx Enhances Multiple Myeloma Risk Profiling with SKY92 Test

SkylineDx's Innovative Contribution to Cancer Diagnosis

SkylineDx has made a significant impact in the field of molecular diagnostics, particularly in oncology. The company's latest research centers around a groundbreaking publication focusing on the SKY92 gene expression profiling test. This innovative tool aims to redefine the understanding of ultra-high-risk multiple myeloma, a complex disease characterized by its variability among patients. Through this publication, which details how SKY92 can be paired with fluorescence in situ hybridization (FISH), SkylineDx highlights its commitment to enhancing cancer diagnostics.

Understanding Multiple Myeloma and the SKY92 Test

Multiple myeloma is a type of blood cancer that affects the plasma cells in the bone marrow. It is known for its heterogeneity, meaning that its progression and aggressiveness can vary greatly among individuals. This variability poses a challenge for accurate diagnosis and treatment. The SKY92 test introduces an effective means of assessing the biological behavior of multiple myeloma through the analysis of 92 specific genes.

The Importance of Gene Expression Profiling

In its recent study, SkylineDx emphasizes the pivotal role that gene expression profiling plays in identifying patients with ultra-high-risk multiple myeloma, particularly in newly diagnosed and relapsed cases. The prospective real-world evidence study has revealed that integrating SKY92 with FISH provides a more precise risk stratification method than what has previously existed in clinical practice.

Improved Treatment Strategies for Patients

By using this combined approach, healthcare professionals can tailor treatment plans more effectively, ensuring that high-risk cases are recognized and managed appropriately. Accurate risk assessment through the SKY92 test allows for risk-adapted treatment strategies, ultimately aiming to improve patient outcomes in a disease where treatment responses can be unpredictable.

Expert Insights and Future Directions

Professor Martin Kortüm, a key figure behind the research, shared insights into the practical application of the SKY92 test in clinical settings. According to him, the test has demonstrated substantial reliability in identifying high-risk patients whose profiles might not be made apparent through traditional FISH methods. This adaptation could lead to the identification of patients who otherwise might miss out on vital interventions.

SkylineDx's Chief Scientific Officer, Jvalini Dwarkasing, echoed this sentiment by emphasizing the collaborative effort that produced these vital research findings, solidifying the company’s role at the forefront of precision medicine. The development solidifies SkylineDx's aim to continuously explore and innovate diagnostic tools that enhance patient care.

The Role of MMprofiler in Understanding Myeloma

MMprofiler, in conjunction with the SKY92 biomarker, is designed to deepen the understanding of multiple myeloma's biological diversity. By measuring gene activity in malignant plasma cells, MMprofiler aims to determine how aggressive the myeloma is. For patients diagnosed with high-risk disease, the implications are clear: these individuals may need more intensive therapy options to combat their illness effectively. The test is CE-IVD registered in Europe and is available from SkylineDx's CAP/CLIA certified laboratory in the USA.

About SkylineDx

SkylineDx is dedicated to the research and development of molecular diagnostics that bridge the gap between academic discoveries and practical, clinically relevant diagnostic tools. From their headquarters in Rotterdam and their laboratory in San Diego, California, they strive to create solutions that facilitate individualized treatment plans based on accurate disease status and patient response predictions.

Frequently Asked Questions

What is the SKY92 test?

The SKY92 test is a gene expression profiling test that measures the activity of 92 genes in plasma cells to determine the aggressiveness of multiple myeloma.

How does SKY92 improve multiple myeloma treatment?

By combining SKY92 with FISH, clinicians can achieve more precise risk stratification, enabling more tailored and effective treatment plans for patients.

What is MMprofiler?

MMprofiler is a molecular diagnostic test that enhances insights into multiple myeloma by evaluating gene expression and assessing disease aggressiveness.

Where is SkylineDx headquartered?

SkylineDx is headquartered in Rotterdam, the Netherlands, with a laboratory in San Diego, California, USA.

Is the SKY92 test available for use?

Yes, the SKY92 test is currently available as a laboratory developed test (LDT) from SkylineDx's certified lab.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 122

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 144

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 100

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 130

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 189

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 73

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 63

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading

Top 5 Most Recently Viewed Articles

Aurora Mobile's Upcoming Earnings Call: What to Expect

Updated Category News Views 155

Aurora Mobile's Upcoming Earnings Call Aurora Mobile Limited (NASDAQ: JG), a prominent player in customer engagement and marketing technology services in China, is set to announce its financial results for the third quarter of 2024 soon. The company will release its unaudited financial report on November 14, 2024, just before the opening of U.S. markets. Details of the...

Continue Reading
Accelerate Financial Technologies Announces New Cash Distributions

Updated Category News Views 122

Accelerate Financial Technologies Announces Cash Distributions Accelerate Financial Technologies Inc. has officially declared the upcoming cash distributions for its Exchange Traded Funds, a positive move aimed at enriching investor portfolios. These distributions, which are set to occur toward the end of 2025, reflect Accelerate's commitment to providing valuable returns...

Continue Reading
Oculis Holding AG: A Focus on Eye Care Innovations

Updated Category News Views 306

Oculis Holding AG Announces Upcoming Investor Conference Oculis Holding AG (NASDAQ: OCS), a cutting-edge biopharmaceutical company dedicated to enhancing eye health and making strides in ocular science, is gearing up for a noteworthy investor conference. The event promises to showcase the latest developments in their innovative research and product initiatives. Event...

Continue Reading
IPC Shares Buyback Program Results Highlight Strong Strategy

Updated Category News Views 154

International Petroleum Corporation's Recent Share Buyback International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) has successfully executed a significant share repurchase program, reinforcing its commitment to enhance shareholder value. From May 12 to 16, IPC repurchased a total of 146,900 common shares, marking a notable phase in its...

Continue Reading
Star Bulk Carriers Plans Upcoming Earnings Release and Call

Updated Category News Views 122

Upcoming Earnings Release for Star Bulk Carriers Star Bulk Carriers Corp., a prominent player in the global shipping industry, is gearing up to announce its financial results for the third quarter. The release is scheduled to take place after the market closes in New York City. Details of the Earnings Announcement The upcoming results, covering the period that ended on...

Continue Reading